Drug intelligence / Profile preview

Repigel

Development stage: Phase 2
Lead developer: Mundipharma Research
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Topical

Overview

Repigel is a 3% liposomal povidone-iodine hydrogel. It is being investigated for its antiseptic properties, primarily for the treatment of inflammatory acne by targeting and eliminating *Proprionibacterium Acnes*, and for managing infected mesh skin grafts by reducing bacterial load and promoting re-epithelialization. The formulation is designed to be cosmetically acceptable, becoming colorless and odorless shortly after topical application. In some regions, it is classified as a medicated device.

Brand names: RepithelRepiGel
Other names: PVP-ILH3% liposomal povidone-iodine hydrogel

Beyond the preview

Go deeper on Repigel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Repigel.

Explore the full profile